United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Wednesday, September 23rd. The shares were sold at an average price of $491.57, for a total transaction of $4,669,915.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at $159,486,445.51. This trade represents a 2.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

United Therapeutics Stock Down 3.5%

United Therapeutics stock opened at $472.21 on Friday. The firm has a market cap of $20.25 billion, a PE ratio of 16.89, a price-to-earnings-growth ratio of 2.49 and a beta of 0.56. United Therapeutics Corporation has a 52-week low of $409.07 and a 52-week high of $609.35. The company’s 50 day moving average is $512.06 and its two-hundred day moving average is $540.50.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. During the same quarter in the previous year, the firm posted $6.41 earnings per share. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, equities research analysts anticipate that United Therapeutics Corporation will post 26.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. JPMorgan Chase & Co. upped their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. The Goldman Sachs Group started coverage on United Therapeutics in a research note on Thursday. They issued a “sell” rating and a $321.00 price objective for the company. Bank of America lowered their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Finally, Royal Bank Of Canada reduced their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $621.00.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of UTHR. BlackRock Inc. acquired a new stake in shares of United Therapeutics in the 2nd quarter valued at about $2,868,735,000. Jupiter Topco LLC purchased a new stake in United Therapeutics in the second quarter valued at approximately $450,140,000. Norges Bank acquired a new stake in shares of United Therapeutics in the fourth quarter valued at approximately $293,418,000. Bank of New York Mellon Corp purchased a new position in shares of United Therapeutics during the second quarter worth approximately $159,522,000. Finally, Caisse de depot et placement du Quebec acquired a new position in shares of United Therapeutics in the 2nd quarter valued at $154,304,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics is using the remainder of its $2 billion share-repurchase authorization through an accelerated share repurchase. The reduced share count could support earnings per share and provide some underlying demand for the stock. United Therapeutics: Strong Catalyst Flow Bodes Well For Near-Term Growth
• Neutral Sentiment: The company’s prior quarter showed better-than-expected earnings, but revenue declined year over year and fell short of estimates. This leaves investors focused on whether newer products can offset pressure on the established pulmonary-hypertension franchise.
• Negative Sentiment: Goldman Sachs initiated coverage with a Sell rating and a $321 price target, arguing that UTHR trades above its long-term valuation range. The call was a significant negative catalyst because it implies substantial downside from recent trading levels. United Therapeutics, Sagimet drop after Goldman issues Sell ratings
• Negative Sentiment: Goldman also highlighted risks involving payer and reimbursement dynamics, potential generic competition, and uncertain real-world adoption of Jenraldi, a newer growth driver. Investors remain concerned that broader coverage requirements for nebulized Tyvaso could limit future revenue growth. United Therapeutics Slips as New Sell Rating Pressures Shares
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $4.7 million, reducing her position by 2.84%. The sale may add to sentiment concerns, particularly alongside reports that company insiders have made numerous sales and no purchases recently, although the transaction could also reflect routine personal or tax-related activity. SEC insider transaction filing

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.